Josep-Lluís Parra

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Violeta Serra, Maurizio Scaltriti, Ludmila Prudkin et al. · Oncogene · 2011 · 534 citations · Full text

Medicine, Cancer Biology, Pharmacology +17

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

Maurizio Scaltriti, Chandra Verma, Marta Guzmán et al. · Oncogene · 2008 · 444 citations

Medicine, Cancer Biology, Oncology +15

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

Violeta Serra, Pieter J.A. Eichhorn, Celina García-García et al. · Journal of Clinical Investigation · 2013 · 140 citations

Medicine, Oncology, Pharmacology +17

The C Terminus of Initiation Factor 4E-Binding Protein 1 Contains Multiple Regulatory Features That Influence Its Function and Phosphorylation

Xuemin Wang, Wěi Li, Josep-Lluís Parra et al. · Molecular and Cellular Biology · 2003 · 111 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i> V659E Mutation

Violeta Serra, Ana Vivancos, Xosé S. Puente et al. · Cancer Discovery · 2013 · 49 citations · Full text

Medicine, Molecular Genetics, Oncology +17